A 72-year-old woman with atrial fibrillation (AF) and normal left ventricular ejection fraction (LVEF 55%) is admitted with a rapid ventricular response of 120 bpm, dyspnea, and chest discomfort. She is hemodynamically stable (BP 130/80 mmHg, alert). Troponin is negative. ECG confirms AF with RVR. After oxygen and IV access, what is the most appropriate next step?

Explanation

## Clinical Scenario Analysis This patient has **hemodynamically stable atrial fibrillation with rapid ventricular response (AF with RVR)** characterized by: - Preserved hemodynamics (BP 130/80, alert) - Negative troponin (no acute MI) - Symptomatic (dyspnea, chest discomfort) but not in shock - Normal LVEF (no heart failure) ## Management Strategy for Stable AF with RVR ```mermaid flowchart TD A[AF with RVR]:::outcome --> B{Hemodynamically stable?}:::decision B -->|No: shock, hypotension, altered LOC| C[Synchronized cardioversion]:::urgent B -->|Yes| D{LVEF reduced <40%?}:::decision D -->|Yes| E[IV amiodarone]:::action D -->|No| F[IV rate-control agent]:::action F --> G{Choose agent}:::decision G -->|No HF, no AV block| H[Beta-blocker or CCB]:::action G -->|HF present| I[Amiodarone or digoxin]:::action H --> J[Diltiazem or verapamil preferred]:::action ``` ## Key Point: **In hemodynamically stable AF with RVR and preserved LVEF, the goal is rate control, not rhythm conversion. IV calcium-channel blockers (diltiazem, verapamil) or beta-blockers are first-line agents.** ## High-Yield: Drug Selection in AF with RVR | Clinical Scenario | First-Line Agent | Rationale | |---|---|---| | Stable, normal LVEF, no HF | Diltiazem or verapamil | Rapid onset (2–5 min), potent AV node blockade | | Stable, reduced LVEF (<40%) | Amiodarone or digoxin | Avoid negative inotropes; amiodarone has class IC properties | | Stable, post-MI or ACS | Beta-blocker (IV metoprolol) | Cardioprotective, reduces ischemia | | Unstable (shock, hypotension, altered LOC) | Synchronized cardioversion | Immediate rhythm conversion | ## Why Diltiazem (or Verapamil)? 1. **Rapid AV nodal blockade** → slows ventricular rate within 2–5 minutes 2. **Negative dromotropic effect** → prolongs AV nodal refractory period 3. **Hemodynamically favorable** → maintains or slightly increases BP (unlike amiodarone) 4. **No proarrhythmic risk** at therapeutic doses 5. **Onset faster than oral agents** (which take 30–60 min) ## Clinical Pearl: **Diltiazem 0.25 mg/kg IV over 2 minutes is the standard dosing for acute AF with RVR.** A second dose of 0.35 mg/kg can be given if rate control is inadequate after 15 minutes. Maintenance infusion (5–15 mg/hr) may follow. ## Why Not Amiodarone Here? Amiodarone is reserved for: - Reduced LVEF (<40%) — where negative inotropes are contraindicated - Hemodynamically unstable AF (post-cardioversion prophylaxis) - Refractory AF despite rate control In this stable patient with normal LVEF, amiodarone is overkill and exposes the patient to unnecessary toxicity (thyroid, lung, liver). ## Why Not Cardioversion? Electrical cardioversion is indicated for **unstable AF** (hypotension, altered mental status, acute MI, cardiogenic shock). This patient is hemodynamically stable and does not meet criteria for urgent rhythm conversion. ## Why Not Oral Metoprolol? Oral agents have a delayed onset (30–60 minutes) and are inappropriate for acute symptomatic tachycardia. IV rate control is needed first; oral therapy can follow once rate is controlled. [cite:Harrison 21e Ch 226; KD Tripathi 8e Ch 12]